Insight into the Enterovirus A71 : A review
© 2022 John Wiley & Sons Ltd..
Enterovirus A71 is a major causative pathogen of hand, foot and mouth disease. It has become a global public health threat, and is especially important for infants and young children in the Asian-Pacific countries. The enterovirus A71 is a non-enveloped virus of the Picornaviridae family having a single-stranded positive-sense RNA genome of about 7.4 kb which encodes the structural and nonstructural proteins. Currently there are no US FDA-approved vaccines or antiviral therapy available against enterovirus A71 infection. Although enterovirus A71 vaccines have been licenced in China, clinically approved vaccines for widespread vaccination programs are lacking. Substantial progress has recently been achieved on understanding the structure and function of enterovirus A71 proteins together with information on the viral genetic diversity and geographic distribution. The present review is intended to provide an overview on our current understanding of the molecular biology and epidemiology of enterovirus A71 which will aid the development of vaccines, therapeutics and other control strategies so as to bolster the preparedness for future enterovirus A71 outbreaks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Reviews in medical virology - 32(2022), 6 vom: 03. Nov., Seite e2361 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kinobe, Robert [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.11.2022 Date Revised 14.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/rmv.2361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340391243 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340391243 | ||
| 003 | DE-627 | ||
| 005 | 20231226005112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rmv.2361 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340391243 | ||
| 035 | |a (NLM)35510476 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kinobe, Robert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insight into the Enterovirus A71 |b A review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.11.2022 | ||
| 500 | |a Date Revised 14.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a Enterovirus A71 is a major causative pathogen of hand, foot and mouth disease. It has become a global public health threat, and is especially important for infants and young children in the Asian-Pacific countries. The enterovirus A71 is a non-enveloped virus of the Picornaviridae family having a single-stranded positive-sense RNA genome of about 7.4 kb which encodes the structural and nonstructural proteins. Currently there are no US FDA-approved vaccines or antiviral therapy available against enterovirus A71 infection. Although enterovirus A71 vaccines have been licenced in China, clinically approved vaccines for widespread vaccination programs are lacking. Substantial progress has recently been achieved on understanding the structure and function of enterovirus A71 proteins together with information on the viral genetic diversity and geographic distribution. The present review is intended to provide an overview on our current understanding of the molecular biology and epidemiology of enterovirus A71 which will aid the development of vaccines, therapeutics and other control strategies so as to bolster the preparedness for future enterovirus A71 outbreaks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Enterovirus A71 | |
| 650 | 4 | |a Picornaviridae | |
| 650 | 4 | |a antiviral agent | |
| 650 | 4 | |a biochemistry | |
| 650 | 4 | |a foot and mouth disease | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a hand | |
| 650 | 4 | |a microbiology | |
| 650 | 4 | |a molecular biology | |
| 650 | 4 | |a molecular epidemiology | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a virology | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 700 | 1 | |a Wiyatno, Ageng |e verfasserin |4 aut | |
| 700 | 1 | |a Artika, I Made |e verfasserin |4 aut | |
| 700 | 1 | |a Safari, Dodi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in medical virology |d 1996 |g 32(2022), 6 vom: 03. Nov., Seite e2361 |w (DE-627)NLM090684788 |x 1099-1654 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2022 |g number:6 |g day:03 |g month:11 |g pages:e2361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rmv.2361 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2022 |e 6 |b 03 |c 11 |h e2361 | ||